Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Purification and characterization of type II heat-labile enterotoxin of Escherichia coli

  • R. K. Holmes
  • , E. M. Twiddy
  • , C. L. Pickett

Producción científica: Article › revisión exhaustiva

44 Citas (Scopus)

Resumen

Type II heat-labile enterotoxin (LT-II) of Escherichia coli has several biologic activities similar to cholera toxin (CT) and E. coli type I heat-labile enterotoxin (LT-I), but it is not neutralized by antiserum prepared against CT or LT-I. LT-II was purified from E. coli SA53 and from E. coli HB101 (pCP3837), a strain that contains the cloned LT-II genes in a hybrid plasmid and produces up to 600 times more LT-II than does SA53. Purification involved sonic disruption of bacterial cells, ammonium sulfate fractionation, chromatography on Affi-Gel Blue, chromatofocusing, and gel filtration on Sephadex G-100. The LT-II purified to apparent homogeneity from HB101 (pCP3837) had an isoelectric point of 6.8, induced increased vascular permeability in rabbit intracutaneous tests, caused rounding of cultured Y1 adrenal cells accompanied by increased intracellular cyclic AMP, and was 25 to 50 times more potent than CT or LT-I in the Y1 adrenal-cell assay. In contrast, purified LT-II did not cause secretion in ligated rabbit ileal segments at does corresponding to CT controls that gave strongly positive reactions. LT-II was composed of two different polypeptides with M(r)s of 28,000 (A) and 11,800 (B); treatment of LT-II with trypsin cleaved the A polypeptide to fragments A1 (M(r), 21,000) and A2 (M(r), 7,000). The activity of LT-II was not blocked by ganglioside GM1 at concentrations that inactivated LT-I or CT. Antiserum against the LT-II from E. coli BH101 (pCP3837) completely neutralized purified LT-II and the LT-II in crude extracts of SA53, but it did not neutralize purified LT-I or CT.

Idioma originalEnglish
Páginas (desde-hasta)464-473
Número de páginas10
PublicaciónInfection and Immunity
Volumen53
N.º3
DOI
EstadoPublished - 1986

Financiación

FinanciadoresNúmero del financiador
National Institute of Allergy and Infectious DiseasesR22AI014107

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Parasitology
    • Microbiology
    • Immunology
    • Infectious Diseases

    Huella

    Profundice en los temas de investigación de 'Purification and characterization of type II heat-labile enterotoxin of Escherichia coli'. En conjunto forman una huella única.

    Citar esto